Q-omics provides the consensus-scored FBXL12 profile across patient tissues and cancer cell-line models. FBXL12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FBXL12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FBXL12 protein abundance shows 29,299 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where FBXL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL12 survival associations across molecular data types. FBXL12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL12 RNA expression–survival associations across cancer types. High FBXL12 expression shows unfavorable associations in ACC, KIRP and LGG, but favorable associations in HNSC, SCLC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FBXL12 RNA expression.
This table summarizes FBXL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL12 shows lower tumor expression in THCA and LUAD and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher FBXL12 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with FBXL12 in patient tissues and cancer cell lines. In patient samples, FBXL12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
